Urgent! What is the price and efficacy of Fengling mixture?

Fengling mixture price: 498.00 yuan Common name: Fengling mixture; Can be used for treating gastric cancer and primary liver cancer due to blood stasis. Description: Fengling mixture is mainly composed of Ficus hirta, Carapax Trionycis, Radix et Rhizoma Rhei and Radix Glycyrrhizae. Attack toxin and disperse knot, promote blood circulation and remove blood stasis. It is suitable for stasis syndrome of advanced gastric cancer which is not suitable for operation, radiotherapy and chemotherapy. The combination of Fengling and chemotherapy drugs has a certain synergistic effect on chemotherapy of gastric cancer with blood stasis and interventional chemotherapy of primary liver cancer with blood stasis. It can improve clinical symptoms and quality of life. Pharmacological action of Fengling mixture: The preclinical pharmacodynamic test shows that this product can inhibit the growth of human cervical cancer cells (Hela), liver cancer cells (7704), gastric cancer cells (790 1) and lung adenocarcinoma cells (al) in vitro. Oral or intraperitoneal injection of this product has a certain anti-tumor effect on C26 mouse transplanted colon cancer, Lewis mouse lung cancer, human liver cancer xenotransplantation and human liver cancer MKN and QFY xenotransplantation models. Oral administration can also inhibit transplanted sarcoma S 180 and H22 liver cancer in mice. Fengling mixture, the clinical benefit rate is as high as 93.2%, and its safety is 4.66 times that of chemotherapy group. A major breakthrough has been made in the field of anti-tumor of traditional Chinese medicine, which has opened up a new way for the treatment and rehabilitation of tumor patients. Fengling mixture has been listed in the medical insurance catalogue for clinical and patient use. Clinical effect of Fengling mixture: short-term effect: improving symptoms. Symptoms such as cancer pain, eating disorder and hydrothorax and ascites can be obviously improved within 3- 15 days. Medium-term effect: improve immunity. After taking 1-2 months, patients can effectively improve white blood cells, have obvious effects of regulating immunity and stimulating bone marrow hematopoiesis, and have obvious synergistic and attenuated effects on patients undergoing radiotherapy and chemotherapy. Long-term effect: inhibit and kill tumors. After 2-3 courses of treatment (4-6 months), it can effectively control the size of cancer focus, inhibit the activity of cancer cells and gradually kill tumors. Adverse reactions of Fengling mixture: a few people have fever, nausea and vomiting. Other main ingredients are hyacinthus orientalis, Carapax Trionycis, Radix et Rhizoma Rhei and Radix Glycyrrhizae. This product is a brown liquid: slightly fragrant and slightly sweet. Administration and dosage: Take orally, each time 15ml, twice a day. The course of treatment is 2 months. Take this product one week before interventional chemotherapy when combined with interventional and embolization chemotherapy for primary liver cancer; When gastric cancer is combined with chemotherapy, start taking this product at the same time as chemotherapy. Fengling mixture is mainly used to attack toxin and disperse stagnation, promote blood circulation and remove blood stasis. It is suitable for stasis syndrome of advanced gastric cancer which is not suitable for operation, radiotherapy and chemotherapy. This product combined with chemotherapy drugs has a certain synergistic effect on chemotherapy of gastric cancer with blood stasis syndrome and interventional chemotherapy and embolization of primary liver cancer with blood stasis syndrome. It can improve clinical symptoms and quality of life. Fengling mixture-a new drug for digestive system tumors such as gastric cancer, intestinal cancer, liver cancer, pancreatic cancer and esophageal cancer. 1, the first therapeutic Chinese medicine for digestive system tumors in China, 18 54 experts' painstaking research. 2. Shanghai medical insurance, a major scientific and technological project, has two patents and independent intellectual property rights. 3. Fengling mixture can effectively improve clinical symptoms and signs, significantly inhibit and kill cancer cells, and improve the quality of life of patients. Shanghai's major scientific and technological project, the first Chinese medicine for treating digestive system tumors in China, has two patents and independent intellectual property rights, and its safety is 4.66 times higher than that of chemotherapy. The principle of treatment is "fight poison with poison". Fengling mixture is the first Chinese medicine with independent intellectual property rights to treat digestive system tumors in China, which fills the gap in the treatment of gastric cancer with Chinese medicine and reaches the international advanced level. The product adopts advanced technologies such as water-alcohol double extraction and cold precipitation, which retains the effective components of Chinese herbal medicines to the maximum extent, greatly improves the scientific and technological content of the product and eliminates the possibility of imitation or counterfeiting. It has the effects of detoxicating, promoting blood circulation and removing blood stasis, and is mainly suitable for the clinical treatment of digestive system tumors such as gastric cancer, liver cancer, pancreatic cancer, intestinal cancer and esophageal cancer, and can also be used for other cancers such as lung cancer, brain cancer, cervical cancer and breast cancer. Clinically, it can be used as the main therapeutic drug alone, or combined with surgery, radiotherapy and chemotherapy and other clinical means for comprehensive treatment. It has the anti-cancer characteristics of "directly killing tumor cells, rapidly improving clinical symptoms, significantly improving the quality of life and effectively prolonging the life of patients". Because there is no similar anticancer drug as a control in China, a controlled trial of Fengling mixture and chemotherapy was carried out in hospitals in Shanghai, Guangzhou, Jiangsu, Zhejiang, Henan and Qinghai for 7 years. The results showed that the clinical total remission rate of Fengling mixture was 3.3 times higher than the national standard and 1 1 times higher than that of the clinical chemotherapy group. The total effective rate is as high as 93.2%, which is nearly 22 percentage points higher than that of chemotherapy group. The effective dose of this product is 1/250 of the toxic dose, and it has no obvious toxic and side effects, and its safety is 4.66 times higher than that of the chemotherapy group. China has made an important breakthrough in the research and development of anticancer drugs with independent intellectual property rights. Fengling mixture, a special drug for treating digestive system tumors such as gastric cancer, was successfully listed in Shanghai. Fengling mixture has been approved by the former Ministry of Health, and has been verified by clinical trials in 12 provincial hospitals nationwide. Its curative effect is better than chemotherapy, reaching the domestic leading and international advanced level, and it is listed as the first therapeutic anticancer Chinese patent medicine in China. Raw materials can be purchased in China, and the project has patents. After approval, it has obtained a new drug certificate. The medicine has obvious therapeutic effect on digestive system cancer, mainly gastric cancer, liver cancer and intestinal cancer, and has no obvious toxic and side effects, especially the tumor inhibition rate of human gastric cancer MKN is above 80%. It can obviously shrink the tumor, relieve the pain of tumor patients, significantly improve the quality of life, prolong the life of patients, and open up a new treatment path for tumor patients. Fengling mixture features: 1. Therapeutic function: Indications for digestive system tumors such as gastric cancer, intestinal cancer, liver cancer, pancreatic cancer and esophageal cancer. It can also be used in combination with cancer symptoms such as lung cancer, breast cancer, cervical cancer and brain tumor, and is especially suitable for patients who are not suitable for radiotherapy and chemotherapy. 2. Conduct clinical trials in many authoritative and well-known cancer hospitals in China. The clinical trial lasted for 7 years, with 600 large samples and 3000 clinical verifications. 3. Treatment remission rate The total clinical remission rate is as high as 26.4%, which is 3.3 times higher than the national standard and higher than the clinical control chemotherapy group 1 1 times. 4. The total clinical effective rate was as high as 93.2%, which was 765,438 0.4% in chemotherapy group, higher than 265,438 0.8% in chemotherapy group. 5. The safety of treatment is 4.66 times higher than that of chemotherapy group, and the effective dose is only 1/250 of the toxic dose. 6, treatment-single treatment, combined with chemotherapy.